FDA Expands Approved Use of Stivarga to Treat Liver Cancer
April 27, 2017
April 27, 2017
WASHINGTON, April 27 -- The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:
The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib. This is the first FDA-approved treatment for a liver cancer in almost a decade.
"Limite . . .
The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib. This is the first FDA-approved treatment for a liver cancer in almost a decade.
"Limite . . .